SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.

Maria Pia SormaniIrene SchiavettiDoriana LandiLuca CarmiscianoNicola De RossiCinzia CordioliLucia MoiolaMarta RadaelliPaolo ImmovilliMarco CapobiancoVincenzo Brescia MorraMaria TrojanoGioacchino TedeschiGiancarlo ComiMario Alberto BattagliaFrancesco Patti Yara Dadalti Fragoso Kerim AslanAksel SivaRoberto Furlan Marco Salvettinull null

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.

Keyphrases

sars cov
immune response
multiple sclerosis
respiratory syndrome coronavirus
mass spectrometry
dendritic cells
white matter
ms ms
toll like receptor
coronavirus disease
newly diagnosed